Exact Sciences Corp. (Nasdaq: EXAS) today announced that James P.
Connelly and Katherine S. Napier have joined the company’s board of
directors.
Mr. Connelly, 62, is a partner in the Foley & Lardner LLP law firm,
where he has served as founding chairman of its Health Law Practice. He
brings to the Exact Sciences’ board of directors more than 25 years
experience providing strategic business and legal advice to large health
care systems, medical group practices, national and regional
laboratories, and emerging biotechnology and life sciences companies. He
was a director of Third Wave Technologies Inc. from 2005 until its
acquisition by Hologic Inc. in 2008. Mr. Connelly earned his bachelor’s
degree from Marquette University and his law degree from the Georgetown
University Law Center, where he was editor-in-chief of the Georgetown
Law Review.
Ms. Napier, 54, is a 20-year veteran of Procter & Gamble, where from
1979 to 2002, she rose from assistant brand manager to vice president
and general manager of the company’s North American pharmaceutical
business. That business experienced unprecedented growth during her
five-year tenure, which included the launch of the osteoporosis drug
Actonel. Actonel grew to $1 billion in revenue more quickly than any of
the company’s brands. Ms. Napier also served as senior vice president of
marketing at McDonald’s Corp., where she led the company’s
reinvigoration of its business with women and families. She received her
bachelor’s degree in economics and studio fine arts from Georgetown
University, and earned a master of business administration degree in
marketing and finance from Xavier University. Ms. Napier serves on the
board of directors of the Alberto Culver Co., Catholic Health Care
Partners, Xavier University, and the board of visitors of Wake Forest
University Calloway School of Business. She was a director of Mentor
Corp. before its acquisition earlier this year by Johnson & Johnson and
of Third Wave Technologies Inc. until its acquisition by Hologic Inc. in
2008.
“We are delighted to welcome Jim and Kay to Exact’s board of directors,”
said Kevin T. Conroy, president and chief executive of Exact. “Both have
impressive sets of experience in their own right. The combination of
Jim’s and Kay’s strategy, financing, technology and marketing
backgrounds, particularly in the molecular diagnostics market, are a
powerful addition to our board at this important time in the company’s
history.”
Michael E. Singer, whose term expires in July, has decided not to stand
for re-election to the board. Mr.
